Group 1 - The National Medical Products Administration (NMPA) has accepted the application for AbbVie Inc.'s Upadacitinib oral solution on February 15, 2026, with acceptance number JXHB2600020 [1] - The application type is a supplementary registration under the chemical drug category, classified as 2.2 [1] - The companies involved in the application include AbbVie Inc. and AbbVie Ireland NL B.V. [1]